AIM
RCKT icon

Acrospire Investment Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Acrospire Investment Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-535
Closed -$4K – 2471
2017
Q1 		$4K Buy
+535
New +$3.6K ﹤0.01% 2043

Other funds holding RCKT

RCP
Rho Capital Partners New York $20.4M AUM
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Acrospire Investment Management's RCKT Position: Q2 2017 in Review

Acrospire Investment Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2017, closing a stake of 535 shares — an estimated $4K sold.

Acrospire Investment Management first reported a position in RCKT in Q1 2017 and held it in 1 quarter. The position peaked at $4K in Q1 2017. 51 funds tracked by Wall St. Rank hold RCKT as of Q2 2017.

  • Acrospire Investment Management reported no remaining Rocket Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 535 Rocket Pharmaceuticals shares in Q2 2017, an estimated $4K.
  • Acrospire Investment Management first reported a position in Rocket Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Rocket Pharmaceuticals position peaked at $4K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.